Click on image to view larger version.

Figure 5 In vitro effects of SU11218. A tyrosine kinase inhibitor, SU11218 inhibited platelet-derived growth factor (PDGF)-stimulated coronary artery smooth muscle cell (CA-SMC) proliferation (A), vascular endothelial growth factor (VEGF)-stimulated coronary artery endothelial cell (CA-EC) proliferation (B), PDGF-stimulated CA-SMC migration (C), and VEGF-stimulated CA-EC migration (D) in a dose-dependent manner. BrdU = bromo-dexoyuridine.